MedTrace Logo

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

NCT01546571 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 504

Last updated 2025-10-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.

Conditions

Interventions

BIOLOGICAL

POL-103A

POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs

BIOLOGICAL

POL-103A without API

Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs

Sponsors & Collaborators

  • Polynoma LLC

    lead INDUSTRY

Principal Investigators

  • Craig Slingluff, M.D. · University of Virginia Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-01
Primary Completion
2021-04-29
Completion
2021-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01546571 on ClinicalTrials.gov